Eli Lilly Commits Over $8 Billion to Alzheimer's Disease R&D to Advance Comprehensive Diagnosis and Treatment Pathways

China Finance and Economics News, March 25 (Reporter Du Ding) -- The 5th International Pharmaceutical Innovation Forum ("IPIF"), co-hosted by the China Center for International Economic Exchanges (CCIEE) and the China Association of Enterprises with Foreign Investment (CAEFI), was held in Beijing.

Eli Lilly and Company Chairman and CEO David A. Ricks, at the global CEO roundtable discussion on "Pharmaceutical Innovation Assisting in Achieving the Healthy China 2030 Goals," shared his insights on "Advancing the Pathway for Innovative Alzheimer's Disease Diagnosis and Treatment in China," emphasizing the importance of shifting the associated healthcare management systems to earlier stages of the disease as breakthrough therapies for Alzheimer’s Disease (AD) continue to innovate.

AD is a neurodegenerative disease with progressive development, and the primary challenge in its prevention and treatment lies in the hidden nature of its symptoms, making early detection difficult. Meanwhile, in China, the management and intervention of this disease currently focus mainly on the late stages, with systems for early detection, diagnosis, and treatment still incomplete. According to statistics, less than half of dementia patients worldwide have received a formal diagnosis, and the majority who remain undiagnosed miss the "golden window" for timely intervention and treatment.

David Ricks stated that AD is the most common cause of dementia and is fatal. Currently, China has nearly 10 million AD patients, and this number is expected to quadruple to 40 million in the next 20 years. This will require significant investment of energy, financial resources, and care from the patients' families, imposing a heavy burden on each household.

"Therefore, we advocate listing AD as a priority in China's national public health agenda, focusing on early detection and diagnosis based on biomarkers, and actively adopting advanced diagnostic technologies such as PET-CT. Second, improve infrastructure both inside and outside medical institutions, and intervene with medications at the early stage of the disease to slow its progression, thereby extending patients' life expectancy and enhancing the efficiency of the healthcare system. Third, include innovative drugs in insurance programs to benefit more patients," said David Ricks. As a global leader and practitioner in the field of neurodegenerative diseases, Eli Lilly has been deeply involved in AD research and development for 35 years, investing over 8 billion US dollars. Meanwhile, Eli Lilly is actively collaborating with all parties to improve the AD diagnosis and treatment pathway and raise public awareness about the disease.

It is reported that, in China, Eli Lilly has continued to communicate with relevant patient organizations and carried out dementia care public welfare activities such as the "Global Employee Volunteer Service Day" over the years. They actively call for society to pay attention to the unmet needs of AD patients, reduce cognitive biases, and increase awareness and support for AD patients and their families.